Enterprise Trust & Investment Co Has $3 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

Enterprise Trust & Investment Co cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,076 shares of the company’s stock after selling 125 shares during the period. Merck & Co., Inc. makes up approximately 1.4% of Enterprise Trust & Investment Co’s investment portfolio, making the stock its 19th largest position. Enterprise Trust & Investment Co’s holdings in Merck & Co., Inc. were worth $2,998,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Catalyst Private Wealth LLC acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth $25,000. Newfound Research LLC bought a new stake in Merck & Co., Inc. during the third quarter worth about $26,000. Fiduciary Planning LLC acquired a new stake in Merck & Co., Inc. during the third quarter worth about $32,000. Stuart Chaussee & Associates Inc. increased its holdings in Merck & Co., Inc. by 44.3% in the 3rd quarter. Stuart Chaussee & Associates Inc. now owns 433 shares of the company’s stock valued at $36,000 after buying an additional 133 shares during the period. Finally, Provident Wealth Management LLC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at about $43,000. Institutional investors and hedge funds own 66.43% of the company’s stock.

Shares of NYSE MRK opened at $82.34 on Thursday. The firm has a 50 day moving average price of $81.41 and a two-hundred day moving average price of $81.11. The stock has a market cap of $208.32 billion, a P/E ratio of 18.22, a price-to-earnings-growth ratio of 1.96 and a beta of 0.43. Merck & Co., Inc. has a 52-week low of $65.25 and a 52-week high of $92.06. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.44 by $0.30. The company had revenue of $12.55 billion for the quarter, compared to analysts’ expectations of $12.21 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. Merck & Co., Inc.’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.51 earnings per share. Analysts predict that Merck & Co., Inc. will post 5.9 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, January 8th. Stockholders of record on Tuesday, December 15th were paid a $0.65 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.61. The ex-dividend date of this dividend was Monday, December 14th. This represents a $2.60 annualized dividend and a dividend yield of 3.16%. Merck & Co., Inc.’s dividend payout ratio is presently 50.10%.

Several analysts recently issued reports on the stock. SVB Leerink increased their price target on shares of Merck & Co., Inc. from $100.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Berenberg Bank started coverage on Merck & Co., Inc. in a report on Tuesday, September 29th. They issued a “hold” rating and a $88.00 target price on the stock. BidaskClub cut Merck & Co., Inc. from a “sell” rating to a “strong sell” rating in a report on Friday, December 18th. Truist assumed coverage on Merck & Co., Inc. in a research report on Friday, October 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $95.36.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Featured Article: Blue-Chip Stocks

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.